EU-”People” Research Training Program in Biotech and Bioethics aim to use IC2 non-invasive imaging of beta-cells mass in studies of induced chemeric immuno tolerence in animal moels of diabetes.
News
Diabetic animal model imaging of the pancreatic beta-cell mass
Welcome to ImmunoSigns
ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.
The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.
© 2019 ImmunoSigns. All Rights Reserved.
Powered by WordPress. Designed by 